{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T06:51:37Z","timestamp":1782370297512,"version":"3.54.5"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[1985,6,1]],"date-time":"1985-06-01T00:00:00Z","timestamp":486432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[1985,6,1]],"date-time":"1985-06-01T00:00:00Z","timestamp":486432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[1985,6]]},"DOI":"10.1007\/bf00174166","type":"journal-article","created":{"date-parts":[[2004,8,15]],"date-time":"2004-08-15T13:54:35Z","timestamp":1092578075000},"page":"173-177","source":"Crossref","is-referenced-by-count":5,"title":["Phase II study of vincristine, mitomycin-C and mitoxantrone in advanced breast cancer: a preliminary report of response and toxicity"],"prefix":"10.1007","volume":"3","author":[{"given":"Timothy J.","family":"Perren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Blackledge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.","family":"Mould","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anula Dharmapriya","family":"Chetiyawardana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Morrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hancock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BF00174166_CR1","first-page":"398","volume-title":"The EORTC Cancer Chemotherapy Annual 5","author":"PP Carbone","year":"1983","unstructured":"Carbone PP: Breast cancer. In HM Pinedo and BA Chabner (eds): The EORTC Cancer Chemotherapy Annual 5. Elsevier, Amsterdam, 1983, pp398\u2013422"},{"key":"BF00174166_CR2","first-page":"444","volume":"22","author":"RV Smalley","year":"1981","unstructured":"Smalley RV, Lefante J, Bartolucci A: CAF vs CMFVP in patients with advanced breast cancer. Proc Am Soc Clin Oncol 22:444, 1981","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF00174166_CR3","first-page":"91","volume-title":"Mitomycin-C \u2014 Current Status and New Developments","author":"TE Godrey","year":"1979","unstructured":"Godrey TE: Mitomycin-C in breast cancer. In SK Carter and ST Crooke (eds): Mitomycin-C \u2014 Current Status and New Developments. Academic Press, New York, 1979, pp91\u2013100"},{"key":"BF00174166_CR4","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2165\/00003495-197816050-00004","volume":"16","author":"TE Davis","year":"1978","unstructured":"Davis TE, Carbone PP: Drug treatment of breast cancer. Drugs 16:441, 1978","journal-title":"Drugs"},{"key":"BF00174166_CR5","first-page":"1","volume":"12","author":"RC Stuart-Harris","year":"1984","unstructured":"Stuart-Harris RC, Bozek T, Pavlidis NA, Smith IE: Mitoxantrone: An active new agent in the treatment of advanced breast cancer. Cancer Chemother Pharmacol 12:1\u20134, 1984","journal-title":"Cancer Chemother Pharmacol"},{"key":"BF00174166_CR6","first-page":"390","volume":"49","author":"RE Coleman","year":"1984","unstructured":"Coleman RE, Rubens RD, Knight RK, Maisey MN: Mitoxantrone in advanced breast cancer \u2014 a phase II study with special attention to cardiotoxicity. Br J Cancer 49:390, 1984","journal-title":"Br J Cancer"},{"issue":"Suppl B","key":"BF00174166_CR7","first-page":"47","volume":"10","author":"JA Neidhart","year":"1983","unstructured":"Neidhart JA, Gochnour D, Young DC: Mitoxantrone versus doxorubicin in advanced breast cancer: a randomised cross-over trial. Cancer Treat Rev 10 (Suppl B):47\u201352, 1983","journal-title":"Cancer Treat Rev"},{"key":"BF00174166_CR8","first-page":"448","volume":"22","author":"MW Oster","year":"1981","unstructured":"Oster MW, Park Y, Grossbard L: Vincristine (V) and mitomycin (M) therapy for previously treated breast cancer. Proc Am Soc Clin Oncol 22:448, 1981","journal-title":"Proc Am Soc Clin Oncol"},{"key":"BF00174166_CR9","unstructured":"World Health Organisation: WHO handbook for reporting results of cancer treatment. WHO offset publication no.48, Geneva, 1979"},{"issue":"Suppl B","key":"BF00174166_CR10","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0305-7372(83)90019-1","volume":"10","author":"RJ Crossley","year":"1983","unstructured":"Crossley RJ: Clinical safety and tolerance of mitoxantrone (Novantrone). Cancer Treat Rev 10 (Suppl B):29\u201336, 1983","journal-title":"Cancer Treat Rev"},{"key":"BF00174166_CR11","first-page":"457","volume":"66","author":"MD Pavy","year":"1982","unstructured":"Pavy MD, Wiely EL, Abeloff MD: Haemolytic-uraemic syndrome associated with mitomycin therapy. Cancer Treat Rep 66:457, 1982","journal-title":"Cancer Treat Rep"},{"key":"BF00174166_CR12","first-page":"77","volume-title":"Mitomycin-C \u2014 Current Status and New Developments","author":"LH Baker","year":"1979","unstructured":"Baker LH, Vaitkevicius VK: The development of an acute intermittent schedule \u2014 Mitomycin-C. In SK Carter and ST Crooke (eds): Mitomycin-C \u2014 Current Status and New Developments. Academic Press, New York, 1979, pp77\u201382"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00174166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF00174166\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00174166","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00174166.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T17:53:10Z","timestamp":1678557190000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF00174166"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,6]]},"references-count":12,"journal-issue":{"issue":"2","published-print":{"date-parts":[[1985,6]]}},"alternative-id":["BF00174166"],"URL":"https:\/\/doi.org\/10.1007\/bf00174166","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,6]]}}}